Else Nutrition H (BABYF) Stock News

Else Nutrition (OTC: BABYF) will host a business update conference call on Tuesday, November 18, 2025 at 10:00 AM ET to discuss third quarter 2025 financial results (period ended September 30, 2025), corporate progress and other developments.

Investors can join by telephone (toll free U.S. 1-877-407-9219; international +1-412-652-1274) or via webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=5ZSyvIjp and the Investor Relations site. A webcast replay will be available on the Investor Relations site through November 18, 2026. A telephone replay will be available about three hours after the call through December 2, 2025 (U.S. 1-877-660-6853; international +1-201-612-7415) using conference ID 13757060.

ELSE NUTRITION (OTCQX:BABYF / TSX:BABY) approved a 1-for-10 share consolidation effective at market open on November 6, 2025. The consolidation will reduce issued and outstanding common shares from 374,114,284 pre-consolidation to approximately 37,411,430 post-consolidation, subject to rounding.

Proportionate adjustments will apply to outstanding stock options, warrants, and other convertibles. New CUSIP 290257500 and ISIN CA2902575000 will apply. Fractional shares will be rounded down if <0.5 and rounded up if ≥0.5. Registered shareholders in certificated form will receive a letter of transmittal from Computershare; DRS holders will receive automatic post-consolidation DRS statements. Non-registered holders should consult their intermediaries. Warrant holders will be notified under the applicable warrant indentures.

Else Nutrition (BABYF) reported its Q2 2025 financial results, showing significant operational challenges but strategic progress. Revenue declined to CAD $1.5 million from CAD $2.6 million in Q2 2024, while gross profit turned negative at -CAD $0.06 million with a -3.7% margin.

The company achieved notable cost reductions, with operating expenses decreasing by 62% to CAD $1.3 million year-over-year. Despite temporary inventory constraints affecting Q2 performance, management highlighted regulatory progress in the US market and ongoing European production transition. The company maintains a cash balance of CAD $0.9 million and targets cash-flow positivity by late 2026 or early 2027.

Else Nutrition Holdings (BABYF) has scheduled a business update conference call for September 16, 2025, at 10:00 a.m. Eastern Time. The call will discuss the company's Q2 2025 financial results and corporate developments.

Investors can access the call via telephone (toll-free 1-877-407-9219 for U.S. callers or +1-412-652-1274 for international callers) or through a webcast. A replay will be available on the company's investor relations website through September 16, 2026, and via telephone through September 30, 2025.

Else Nutrition (OTCQX: BABYF) reported its Q1 2025 financial results, maintaining revenue at $2.1 million year-over-year while significantly improving operational efficiency. The company achieved a notable reduction in operating expenses by 48% to $2.2 million and increased gross profit margin to 25% from 8% in Q1 2024.

Key strategic initiatives include shifting powder formula manufacturing to Europe to reduce production costs and improve margins. The company is also optimizing its retail distribution model and pursuing regulatory advancement through Operation Stork Speed and the FY2026 Agriculture Appropriations Bill, which could streamline FDA approval pathways for plant-based infant nutrition alternatives.

The company ended Q1 2025 with a cash balance of $0.2 million, including restricted cash, and is exploring strategic collaborations to accelerate growth.

Else Nutrition (OTCQX: BABYF) has scheduled a business update conference call for Thursday, August 21, 2025, at 10:00 a.m. Eastern Time. The call will discuss the company's Q1 2025 financial results and corporate developments.

Investors can access the call via telephone (toll-free: 1-877-407-9219 for U.S. callers; +1-412-652-1274 for international) or webcast. A replay will be available through August 21, 2026, on the company's investor relations website, with telephone replay accessible until September 3, 2025.

Else Nutrition Holdings (OTCQX:BABYF) has received approval from the Toronto Stock Exchange for an additional extension to hold its 2025 Annual General Meeting (AGM). The company, which previously announced a delay on June 19, 2025, is now required to conduct the AGM by September 30, 2025.

Else Nutrition (OTCQX: BABYF) welcomes a significant legislative development as the U.S. House Appropriations Committee passes the FY2026 Agriculture and FDA Appropriations Bill. The legislation specifically directs the FDA to streamline approval pathways for plant-based, non-soy, and non-dairy infant formulas.

The bill includes crucial language supporting alternative infant formula access and calls for formal regulatory guidance for non-dairy, non-soy plant-based formulas. This initiative is part of Operation Stork Speed, the Administration's effort to accelerate innovation in infant formula. While the legislation still needs full House approval, it represents a significant step toward expanding the U.S. infant formula market and potentially expediting Else Nutrition's market access.

Else Nutrition Holdings (BABYF) has received a cease trade order (CTO) from the British Columbia Securities Commission due to delayed filing of its Q1 2025 financial statements and related documents. The CTO prohibits trading of company securities in Canada until the interim filings are completed and the order is revoked. Limited exceptions exist for non-insider beneficial shareholders who acquired securities before June 16, 2025, allowing sales through foreign regulated markets via registered Canadian investment dealers. The company expects to file the required documents by June 30, 2025. Additionally, the Toronto Stock Exchange has granted an extension for the company's annual general meeting from June 30 to July 31, 2025.